SABS
SAB Biotherapeutics, Inc. Common StockstockNASDAQ
Market OpenNov 19, 2026 3:43:51 PM EST
2.82USD-11.875%(-0.38)1,603,921
SABS Financials
In Q3 FY 2026 (ended ), SAB Biotherapeutics, Inc. Common Stock (SABS) reported revenue of $0, net income of −$22.3M, operating cash flow of −$13.02M, and assets of $235.64M (filed ).
Loading financial flows…